| CAC 40 Moderately Lower; STMicroelectronics, Renault Decline Sharply | BRUSSELS (dpa-AFX) - Despite recovering from early lows, the French stock market's benchmark index CAC 40 remained in negative territory a little past noon, weighed down by a sharp decline in... ► Artikel lesen |
| Aktien Europa: Klare Verluste im Sog der asiatischen Börsen - Tech unter Druck | PARIS/LONDON/ZÜRICH (dpa-AFX) - Die schwachen asiatischen Börsen haben die europäischen Märkte am Dienstag nur teilweise in Mitleidenschaft gezogen. Auch in den USA zeichnen sich Kursverluste ab. Durch... ► Artikel lesen |
| AKTIEN IM FOKUS 2: Anleger lassen Luft aus KI-Aktien - Suss Microtec brechen ein | (neu: Kurse aktualisiert und weitere Kurse ergänzt) FRANKFURT/SEOUL (dpa-AFX Broker) - Herbe Kursverluste an der südkoreanischen Börse haben am Dienstag auch an Europas Aktienmärkten ihre Spuren... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen |
| Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer | SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA)... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen |